drugset / Trial / NCT00835380

A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)

NCT00835380

Phase 3 Completed 80 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This study will demonstrate the immunogenicity and evaluate the safety/tolerability of the vaccine in Chinese children between 12 and 23 months of age.

Timeline

Start
2008-03
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vaqta Vaccine 25 iu Intramuscular